Carden MA, Gaddh M, Hoskote A, et al. Rituximab leads to early elimination of circulating CD20(+) T and B lymphocytes in patients with iTTP despite ongoing TPEx. Blood Adv. 2020;4(3):477-481.

Documenti analoghi

• Rituximab leads to early elimination of circulating CD20(+) T and B lymphocytes in patients with iTTP despite ongoing TPEx
  di: Carden, Marcus A., et al.
  Pubblicazione: (2020)
• Outcomes of Immune Thrombotic Thrombocytopenic Purpura (iTTP) With Upfront Cyclophosphamide vs. Rituximab
  di: Abou-Ismail, Mouhamed Yazan, et al.
  Pubblicazione: (2020)
• Assessment and Monitoring of Patients with Immune-Mediated Thrombotic Thrombocytopenic Purpura (iTTP): Strategies to Improve Outcomes
  di: Kucukyurt, Selin, et al.
  Pubblicazione: (2020)
• Adjuvant low-dose rituximab and plasma exchange for acquired TTP
  di: Zwicker, Jeffrey I., et al.
  Pubblicazione: (2019)
• First report of a de novo iTTP episode associated with an mRNA‐based anti‐COVID‐19 vaccination
  di: de Bruijn, Sévérine, et al.
  Pubblicazione: (2021)